Top-Rated StocksTop-RatedNASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free RARE Stock Alerts $40.14 +1.49 (+3.86%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$39.14▼$40.7450-Day Range$38.14▼$51.6152-Week Range$31.52▼$54.98Volume1.52 million shsAverage Volume666,359 shsMarket Capitalization$3.34 billionP/E RatioN/ADividend YieldN/APrice Target$90.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ultragenyx Pharmaceutical alerts: Email Address Ultragenyx Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside125.9% Upside$90.67 Price TargetShort InterestHealthy5.22% of Shares Sold ShortDividend StrengthN/ASustainability-2.28Upright™ Environmental ScoreNews Sentiment0.76Based on 20 Articles This WeekInsider TradingSelling Shares$1.20 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.49) to ($4.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.62 out of 5 starsMedical Sector65th out of 928 stocksPharmaceutical Preparations Industry23rd out of 437 stocks 4.5 Analyst's Opinion Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ultragenyx Pharmaceutical's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.22% of the outstanding shares of Ultragenyx Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently decreased by 6.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUltragenyx Pharmaceutical has received a 49.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Triheptanoin", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ultragenyx Pharmaceutical is -2.28. Previous Next 2.6 News and Social Media Coverage News SentimentUltragenyx Pharmaceutical has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Ultragenyx Pharmaceutical this week, compared to 5 articles on an average week.Search Interest27 people have searched for RARE on MarketBeat in the last 30 days. This is an increase of 1,250% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,201,388.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ultragenyx Pharmaceutical's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($6.49) to ($4.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 23.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ultragenyx Pharmaceutical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Read More RARE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RARE Stock News HeadlinesJune 2 at 6:08 AM | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) PT Raised to $111.00 at Canaccord Genuity GroupJune 2 at 5:26 AM | americanbankingnews.comCantor Fitzgerald Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $115.00June 2 at 4:00 AM | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) PT Raised to $48.00June 2 at 2:54 AM | americanbankingnews.comRobert W. Baird Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $72.00June 1 at 7:18 AM | americanbankingnews.comBank of America Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $76.00June 1 at 6:20 AM | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $127.00June 1 at 2:44 AM | americanbankingnews.comAnalysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) PT at $87.85May 30 at 4:00 PM | globenewswire.comUltragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)May 23, 2024 | benzinga.comUltragenyx Pharmaceutical Stock (NASDAQ:RARE), Quotes and News SummaryMay 22, 2024 | finance.yahoo.comUltragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' CellsMay 17, 2024 | globenewswire.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Ultragenyx’s Gene Therapy Shows Promising Efficacy and Safety ProfilesMay 8, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)May 7, 2024 | finance.yahoo.comUltragenyx to Participate at Bank of America’s 2024 Healthcare ConferenceMay 4, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter ResultsMay 4, 2024 | insidermonkey.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call TranscriptMay 4, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)May 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)May 3, 2024 | markets.businessinsider.comWedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)May 3, 2024 | finance.yahoo.comUltragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...May 2, 2024 | sfgate.comUltragenyx: Q1 Earnings SnapshotMay 2, 2024 | msn.comUltragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28, revenue of $108.8M misses by $7.64MMay 2, 2024 | investorplace.comRARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024May 2, 2024 | globenewswire.comUltragenyx Reports First Quarter 2024 Financial Results and Corporate UpdateApril 30, 2024 | globenewswire.comUltragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare DiseaseSee More Headlines Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/02/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RARE CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,276Year Founded2010Price Target and Rating Average Stock Price Target$90.67 High Stock Price Target$133.00 Low Stock Price Target$48.00 Potential Upside/Downside+125.9%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($8.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-606,640,000.00 Net Margins-138.58% Pretax Margin-139.01% Return on Equity-425.63% Return on Assets-45.88% Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio2.28 Sales & Book Value Annual Sales$434.25 million Price / Sales7.68 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book23.75Miscellaneous Outstanding Shares83,130,000Free Float78,311,000Market Cap$3.34 billion OptionableOptionable Beta0.68 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Emil D. Kakkis M.D. (Age 64)Ph.D., Founder, President, CEO & Director Comp: $1.46MMr. Howard Horn (Age 46)Executive VP of Corporate Strategy & CFO Comp: $184.81kMs. Karah Herdman Parschauer J.D. (Age 46)Chief Legal Officer & Executive VP of Corporate Affairs Comp: $846.74kMr. John Richard Pinion II (Age 58)Chief Quality Operations Officer & Executive VP of Translational Sciences Comp: $860.05kMr. Erik Harris (Age 53)Executive VP & Chief Commercial Officer Comp: $878.77kMr. Theodore A. Huizenga (Age 53)Senior VP, Corporate Controller & Principal Accounting Officer Mr. Ernie W. Meyer (Age 59)Chief Human Resources Officer & Executive VP Mr. Thomas R. Kassberg (Age 64)Chief Business Officer & Executive VP Comp: $714.84kMr. Vimal Srivastava (Age 59)Senior Vice President of Business Development & Alliance Management Mr. Dennis Karl Huang (Age 59)Chief Technical Operations Officer and EVP of Gene Therapy Research & Development Comp: $331.33kMore ExecutivesKey CompetitorsACADIA PharmaceuticalsNASDAQ:ACADMirati TherapeuticsNASDAQ:MRTXBausch Health CompaniesNYSE:BHCViatrisNASDAQ:VTRSUnited TherapeuticsNASDAQ:UTHRView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckyBought 14,792 shares on 5/28/2024Ownership: 0.018%Farallon Capital Management LLCBought 99,000 shares on 5/24/2024Ownership: 0.119%Artal Group S.A.Bought 177,932 shares on 5/17/2024Ownership: 0.214%Motley Fool Asset Management LLCSold 2,917 shares on 5/17/2024Ownership: 0.176%Walleye Trading LLCSold 3,800 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RARE Stock Analysis - Frequently Asked Questions Should I buy or sell Ultragenyx Pharmaceutical stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RARE shares. View RARE analyst ratings or view top-rated stocks. What is Ultragenyx Pharmaceutical's stock price target for 2024? 14 equities research analysts have issued 1 year price targets for Ultragenyx Pharmaceutical's stock. Their RARE share price targets range from $48.00 to $133.00. On average, they anticipate the company's stock price to reach $90.67 in the next twelve months. This suggests a possible upside of 125.9% from the stock's current price. View analysts price targets for RARE or view top-rated stocks among Wall Street analysts. How have RARE shares performed in 2024? Ultragenyx Pharmaceutical's stock was trading at $47.82 at the start of the year. Since then, RARE stock has decreased by 16.1% and is now trading at $40.14. View the best growth stocks for 2024 here. When is Ultragenyx Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our RARE earnings forecast. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by $0.31. The biopharmaceutical company had revenue of $108.83 million for the quarter, compared to the consensus estimate of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative trailing twelve-month return on equity of 425.63%. Ultragenyx Pharmaceutical's revenue was up 8.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.33) earnings per share. What ETFs hold Ultragenyx Pharmaceutical's stock? ETFs with the largest weight of Ultragenyx Pharmaceutical (NASDAQ:RARE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Tema Cardiovascular and Metabolics ETF (HRTS), Motley Fool Small-Cap Growth ETF (TMFS), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Mid-Cap Growth ETF (TMFM), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA) and Simplify Health Care ETF (PINK). What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings? Ultragenyx Pharmaceutical issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $500.0 million-$530.0 million, compared to the consensus revenue estimate of $513.0 million. What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO? 41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM). Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.47%), Price T Rowe Associates Inc. MD (4.29%), Clearbridge Investments LLC (2.89%), Avoro Capital Advisors LLC (1.00%), First Light Asset Management LLC (0.95%) and Jacobs Levy Equity Management Inc. (0.83%). Insiders that own company stock include Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Eric Crombez, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Theodore Alan Huizenga and Thomas Richard Kassberg. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RARE) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.